[关键词]
[摘要]
目的 探讨骨疏康胶囊联合利塞膦酸钠治疗绝经后骨质疏松症的临床疗效。方法 选取2019年1月—2020年1月在河南理工大学第一附属医院(焦作市第二人民医院)进行诊治的114例绝经后骨质疏松症患者为研究对象,根据就诊顺序随机分为对照组(57例)和治疗组(57例)。对照组餐前30 min直立位口服利塞膦酸钠片,5 mg/次,1次/d。治疗组在对照组基础上口服骨疏康胶囊,4粒/次,2次/d。两组均经过6个月治疗。观察两组的临床疗效,比较两组治疗前后相关评分、骨密度和骨代谢指标的变化情况。结果 经治疗,治疗组总有效率96.49%,显著高于对照组的84.20%(P<0.05)。经治疗,两组VAS评分显著降低,而SF-36评分显著升高(P<0.05);治疗后,治疗组VAS评分低于对照组,而SF-36评分高于对照组(P<0.05)。经治疗,两组L2~4及股骨颈骨密度均较治疗前显著增加(P<0.05);治疗后,治疗组骨密度高于对照组(P<0.05)。经治疗,两组血清骨钙素(BGP)、抗酒石酸酸性磷酸酶(TRACP-5b)、骨保护素(OPG)、β-胶原降解产物(β-CTX)水平均较治疗前显著降低,但骨碱性磷酸酶(B-ALP)、I型前胶原氨基端原肽(PINP)显著升高(P<0.05);且治疗后,治疗组这些骨代谢指标显著优于对照组(P<0.05)。结论 骨疏康胶囊联合利塞膦酸钠治疗绝经后骨质疏松症具有较好的临床疗效,可显著改善患者临床症状,抑制骨吸收、促进骨形成,提高骨密度及患者生活质量,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the effect of Gushukang Capsules combined with risedronate sodium in treatment of postmenopausal osteoporosis. Methods 114 Cases of postmenopausal osteoporosis patients diagnosed and treated in the First Affiliated Hospital of Henan Polytechnic University (Jiaozuo Second People's Hospital) from January 2019 to January 2020 were selected as research objects, and randomly divided into control group (57 cases) and treatment group (57 cases) according to the order of treatment. The control group po administered with Risedronate Sodium Tablets at an upright position 30 min before meal, 5 mg/time, once daily. Patients in the treatment group were po administered with Gushukang Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 6 months. The clinical efficacy of the two groups was observed, and the changes of relevant scores, bone mineral density and bone metabolism indexes before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 96.49%, significantly higher than that of the control group (84.20%, P<0.05). After treatment, VAS score was significantly decreased in both groups, while SF-36 score was significantly increased (P<0.05). After treatment, VAS score in the treatment group was lower than that in the control group, while SF-36 score was higher than that in the control group (P<0.05). After treatment, the BMD of L2-4 and femoral neck in both groups was significantly higher than that before treatment (P<0.05). After treatment, bone mineral density in the treatment group was higher than that in the control group (P<0.05). After treatment, the serum levels of BGP, TRACP-5b, OPG, β-CTX in both groups were significantly lower than those before treatment, but B-ALP and PINP were significantly higher (P<0.05). After treatment, these bone metabolism indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Gushukang Capsules combined with risedronate sodium has good clinical effect in treatment of postmenopausal osteoporosis, and can significantly improve patients' clinical symptoms, inhibit bone absorption, and also can promote bone formation, improve bone density and patients' life quality, which has certain clinical application value.
[中图分类号]
R977
[基金项目]
河南省医学科技攻关计划联合共建项目(LHGJ20191356)